Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bb9ee02ff15ab8c1e3729cb182854ff39> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bb9ee02ff15ab8c1e3729cb182854ff39 NCIT_P378 "NCI" @default.
- Bb9ee02ff15ab8c1e3729cb182854ff39 type Axiom @default.
- Bb9ee02ff15ab8c1e3729cb182854ff39 annotatedProperty IAO_0000115 @default.
- Bb9ee02ff15ab8c1e3729cb182854ff39 annotatedSource NCIT_C201084 @default.
- Bb9ee02ff15ab8c1e3729cb182854ff39 annotatedTarget "An inhalation powder formulation composed of a fixed combination of the furoate salt form of the glucocorticoid fluticasone, the bromide salt form of the muscarinic receptor antagonist umeclidinium, and the triphenylacetate salt form of the long-acting beta-2 adrenergic agonist vilanterol, with anti-inflammatory and bronchodilator activities. Upon oral inhalation of the fluticasone furoate/umeclidinium bromide/vilanterol trifenatate inhalation powder via an inhaler, fluticasone binds to intracellular glucocorticoid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with inflammation. Umeclidinium antagonizes M3 muscarinic receptors located on smooth muscle cells, thereby preventing smooth muscle contraction and resulting in bronchodilation. Vilanterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells." @default.